drugset / Trial / NCT04253626
Comparison of Oral Ferrous Sulfate to Intravenous Ferumoxytol in Antepartum Iron Deficiency Anemia
Phase 3
Completed
83 enrolled
Stanford University
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Evaluate the extent to which treatment of iron deficiency anemia beyond 24-34 weeks' gestation of pregnancy with intravenous iron increases hemoglobin compared to oral iron. The investigators will test the hypothesis that pregnant women who are anemic in the second and third trimester are more likely to significantly increase their hemoglobin with intravenous iron as opposed to the usual standard of care, oral iron.
Timeline
- Start
- 2021-01-21
- Primary completion
- 2024-07-01
- Completion
- 2024-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ferrous Sulfate | Diagnostic / imaging agent | 325 mg | Oral |
| Comparator | Ferrous Sulfate | Diagnostic / imaging agent | 650 mg | Oral |
| Subject | Ferumoxytol | Diagnostic / imaging agent | 510 mg | Intravenous |
| Subject | Ferumoxytol | Diagnostic / imaging agent | 1020 mg | Intravenous |